Simulation shows impact of increased PSA testing on prostate cancer diagnosisJune 1, 2021Prostate Cancer
PSMA therapy promotes similar prostate cancer survival regardless of regimenJune 1, 2021Prostate Cancer
Healthy lifestyle may offset genetic risk in prostate cancerApril 13, 2021Genitourinary CancerOncologyProstate Cancer
CCR score can guide treatment decisions after radiation in prostate cancerFebruary 13, 2021Genitourinary CancerProstate CancerOncology
Declines in PSA screening may account for rise in metastatic prostate cancersFebruary 12, 2021Genitourinary CancerOncologyProstate Cancer
Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized MedicineJanuary 7, 2021Lung CancerOncologyProstate Cancer
FDA approves first agent for PSMA-PET imaging in prostate cancerDecember 2, 2020Genitourinary CancerProstate CancerOncology
The Effect of Radium-223 Therapy in Agent Orange-Related Prostate CarcinomaNovember 6, 2020OncologyProstate Cancer
Cancer therapy affects sexual health in most patientsOctober 29, 2020Breast CancerGenitourinary CancerWomen's HealthProstate Cancer
Understanding De-Implementation of Low Value Castration for Men With Prostate CancerSeptember 2, 2020OncologyProstate Cancer
The Impact of Sequencing of Abiraterone and Enzalutamide in Veterans With Metastatic Castration- Resistant Prostate CancerSeptember 2, 2020OncologyProstate Cancer
The Impact of Sequencing of Abiraterone and Enzalutamide in Veterans With Metastatic Castration- Resistant Prostate CancerSeptember 2, 2020OncologyProstate Cancer
Prostate-Specific Antigen Decline >50% After 4 Weeks of Treatment Is an Indicator of Better Progression Free and Overall Survival Both With Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate CancerSeptember 2, 2020OncologyProstate Cancer
